Use of Treprostinil to treat neuropathic diabetic foot ulcers
The present invention describes novel methods for using 9-deoxy-2′,9-α-methano-3-oxa-4,5,6-trinor-3,7-(1′,3′-interphenylene)-13,14-dihydro-prostaglandin F 1 (also known as Treprostinil) or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of foot ulcers in subjects with diabetic neuropathy. The invention also relates to kits for treatment and/or prevention of foot ulcers, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
1. A method for treating a diabetic neuropathic foot ulcer, comprising administering to a subject with diabetic neuropathy in need thereof an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, wherein said derivative is a sustained release form of Treprostinil, an inhaled form of Treprostinil, an oral form of Treprostinil or an acid derivative of Treprostinil, wherein the subject has diabetic neuropathy but not peripheral vascular disease.
2. The method of claim 1 , wherein said administering results in symptoms associated with the diabetic neuropathic foot ulcer in the subject being reduced or eliminated.
3. The method of claim 1 , wherein said administering is administering to the subject an effective amount of a pharmaceutically acceptable salt of Treprostinil.
4. The method of claim 1 , wherein the subject is a human being.
5. The method of claim 1 , wherein said administering is subcutaneous administering.
6. The method of claim 1 , wherein said administering is administering by continuous subcutaneous infusion.
7. The method of claim 1 , wherein said administering is intravenous administering.
8. The method of claim 1 , wherein said administering is administering in an orally available form selected from the group consisting of tablets and capsules.
9. The method of claim 1 , wherein said administering is administering by inhalation.
10. The method of claim 1 , wherein the effective amount is at least 1.0 ng/kg of body weight/min.
11. A method for reducing or eliminating a pain associated with or caused by a diabetic neuropathic foot ulcer comprising administering to a subject with diabetic neuropathy in need thereof an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, wherein said derivative is a sustained release form of Treprostinil, an inhaled form of Treprostinil, an oral form of Treprostinil or an acid derivative of Treprostinil, wherein the subject has diabetic neuropathy but not peripheral vascular disease.
12. The method of claim 11 , wherein said administering is administering to the subject an effective amount of a pharmaceutically acceptable salt of Treprostinil.
13. The method of claim 11 , wherein the subject is a human being.
14. The method of claim 11 , wherein said administering is subcutaneous administration.
15. The method of claim 11 , wherein said administering is administering by continuous subcutaneous infusion.
16. The method of claim 11 , wherein said administering is intravenous administering.
17. The method of claim 11 , wherein said administering is administering in an orally available form selected from the group consisting of tablets and capsules.
18. The method of claim 11 , wherein said administering is administering by inhalation.
19. The method of claim 11 , wherein the effective amount is at least 1.0 ng/kg of body weight/min.
20. The method of claim 1 , wherein said administering comprises orally administering to the subject an oral formulation comprising diethanolamine salt of treprostinil.
21. The method of claim 11 , wherein said administering comprises orally administering to the subject an oral formulation comprising diethanolamine salt of treprostinil.